Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial - Wikidata - wikimedia - TriplyDB

Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial

Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial

http://www.wikidata.org/entity/Q33903527

about

The Prevalence and Management of Systemic Amyloidosis in Western Countries Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis Functional Amyloid Signaling via the Inflammasome, Necrosome, and Signalosome: New Therapeutic Targets in Heart Failure Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis Infiltrative Cardiomyopathies Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs Nuclear imaging modalities for cardiac amyloidosis Aromatic Sulfonyl Fluorides Covalently Kinetically Stabilize Transthyretin to Prevent Amyloidogenesis while Affording a Fluorescent Conjugate AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade Stilbene Vinyl Sulfonamides as Fluorogenic Sensors of and Traceless Covalent Kinetic Stabilizers of Transthyretin That Prevent Amyloidogenesis First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy Engineering enhanced protein disaggregases for neurodegenerative disease Endoplasmic reticulum quality control and systemic amyloid disease: Impacting protein stability from the inside out Evolving landscape in the management of transthyretin amyloidosis Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial The flavonoid luteolin, but not luteolin-7-O-glucoside, prevents a transthyretin mediated toxic response Modifications of the 7-Hydroxyl Group of the Transthyretin Ligand Luteolin Provide Mechanistic Insights into Its Binding Properties and High Plasma Specificity Tetrabromobisphenol A Is an Efficient Stabilizer of the Transthyretin Tetramer Transthyretin-Related Familial Amyloid Polyneuropathy (TTR-FAP): A Single-Center Experience in Sicily, an Italian Endemic Area Transthyretin Cardiac Amyloidosis in Older Americans.Safety and efficacy of long-term diflunisal administration in hereditary transthyretin (ATTR) amyloidosis.Physiological IgM class catalytic antibodies selective for transthyretin amyloid.Gene expression profile in hereditary transthyretin amyloidosis: differences in targeted and source organs Corino de Andrade disease: mechanisms and impact on reproduction.Guideline of transthyretin-related hereditary amyloidosis for clinicians.Quantification of quaternary structure stability in aggregation-prone proteins under physiological conditions: the transthyretin case.Novel drugs targeting transthyretin amyloidosis.FAP neuropathy and emerging treatments.Recent progress in the understanding and treatment of transthyretin amyloidosis.Surface effects mediate self-assembly of amyloid-β peptides.An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis.Curcumin could reduce the monomer of TTR with Tyr114Cys mutation via autophagy in cell model of familial amyloid polyneuropathy.Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.Neurophysiological markers of small fibre neuropathy in TTR-FAP mutation carriers.Recent advances in transthyretin amyloidosis therapy Neurophysiological techniques to detect early small-fiber dysfunction in transthyretin amyloid polyneuropathy.Transthyretin cardiac amyloidosis: pathogenesis, treatments, and emerging role in heart failure with preserved ejection fraction.A woman with a rare p.Glu74Gly transthyretin mutation presenting exclusively with a rapidly progressive neuropathy: a case report.Unfolded protein response-induced ERdj3 secretion links ER stress to extracellular proteostasis.

P2860

Q26740436-8EF21BB9-706C-4968-90F4-04587DB84BBE Q26764754-946CC032-24E6-4494-8573-255E4D062F18 Q26776120-AD099BA1-0C0D-49A2-AD07-6779E5AFFB1A Q26782089-C5318410-17CE-4D44-AE57-A60B35D35B8D Q26798533-870C5E42-8C6C-459A-90A4-E9596127E7E2 Q27009309-4FF6F34A-6780-4E3E-9A50-FFF58331A0BE Q27024756-89F1D8FA-78CB-4270-B907-25EEBA5F76D4 Q27675997-04DC0DF9-A519-4B8C-B6DA-67554259709B Q27678369-606B135C-0011-4EB2-9D5B-38BD7832EE5A Q27679360-67B94D6C-5F5C-4B2F-9FF7-099EF108E8B7 Q27680500-8E4D2ED2-B831-4A8F-AE9B-322FBA7EDE9F Q28071522-5B8AFDA8-E289-442D-8A6E-FF36659DE211 Q28083809-4F2BAC5A-58DC-4170-B4CA-C8E1D711802D Q28084013-FD4C73B0-96E5-4076-A97B-7906BAAFC25A Q28086773-73F48AAB-AA0A-4D40-B5AC-AA7E1310946D Q28304712-74F9DA2A-4983-468C-A701-9636AE805610 Q28547541-D96CAF27-E9BE-4F99-ACFB-E17DA19ED79A Q28551199-BF901CD8-9C0B-47F7-BCE6-65CBCD948A1D Q28551432-082CABBF-4790-43BD-B161-186C74EF399B Q29248271-6696A450-08A5-4EAF-9512-671D5876BE4A Q30244227-04AD5C16-4162-4223-AC3A-AEBDD6E89F22 Q33423160-C18E8D9C-E05A-4554-9DD5-321698B4E267 Q33676625-F94448DA-8F89-41B5-9025-F5E04F8C66CA Q33716349-05E67872-C502-4054-B08E-CCA571469BF1 Q33807480-CA752F04-4B00-4FA7-9044-4B51E37F07B0 Q34328734-8CF5973B-84C6-409E-8E1D-C86D1160B50A Q34379670-0651F371-1B28-4609-A2E7-06A77ADC5E4B Q34400138-A3EF57C1-FDA3-4E57-900F-44E7A20CD15A Q34401190-4756E198-A77F-43D4-9BCE-4608954A1E73 Q34416193-5E4079B3-BE26-440D-AFE3-0F1E12503DDC Q34419863-F6A2330C-02C9-4DB0-A093-AC36D198ED06 Q34428314-A9A1F1FC-665C-4589-9DD5-FBD023313CD8 Q34464337-4D5EE74B-4213-463A-8E9C-ED2885DF91AC Q34487487-B2399279-D678-4F29-973B-800759E4858A Q34544072-E2C3DA11-B562-4B9D-974C-3671DDF9D14C Q34664696-DDC82873-6DD6-47A2-B9CC-AB4CA2818B92 Q34726962-0B69D3BC-64EF-4E63-9A1B-EC4B02C3E49F Q34838524-DB41BB0D-D1E4-4A2C-8F8A-483A0F12DB80 Q34894825-82E9AD12-0EBE-41CC-B295-CDB7095F431A Q34923990-BD8EE05D-D7A5-4182-BF78-162CD4876A4C

P2860

Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial

http://www.wikidata.org/entity/Q33903527

description

2012 nî lūn-bûn

@nan

2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Tafamidis for transthyretin fa ...... a randomized, controlled trial

@ast

Tafamidis for transthyretin fa ...... a randomized, controlled trial

@en

type

label

Tafamidis for transthyretin fa ...... a randomized, controlled trial

@ast

Tafamidis for transthyretin fa ...... a randomized, controlled trial

@en

prefLabel

Tafamidis for transthyretin fa ...... a randomized, controlled trial

@ast

Tafamidis for transthyretin fa ...... a randomized, controlled trial

@en

P1433

Q33903527-D0256F29-DE2D-4E59-9818-070C75387673

P1476

Q33903527-FFDDC044-6BD7-4F1E-B16D-0043696D72B4

P2093

Q33903527-024CE49F-C26B-4A06-AEF9-8126A7B7427C

Q33903527-222F48BA-3BA6-4DE5-B833-A12DC0597983

Q33903527-45DC2235-2E60-4AFF-AE8C-7DA32AEE8424

Q33903527-4C96F143-C58D-4B77-AC29-A0673CD58406

Q33903527-5DD26D72-EBC7-4E88-B918-BE07DC0F2B59

Q33903527-6430CFBF-FC93-491F-B0BB-55CD1DADCDC1

Q33903527-7BBBDE6D-E5B5-4200-94A9-1171484914F4

Q33903527-7D319D9F-BB30-49C3-B248-0E37B184DCDA

Q33903527-AC8032A6-AAA1-4FC4-B556-66EE8DD13630

Q33903527-B83C540E-D961-4F64-9380-4093AE8BF820

P2860

Q33903527-133ACBD0-044F-49DC-8C4D-1076E5E9A582

Q33903527-2129FA44-B856-4C1C-AE1C-1352BA59901B

Q33903527-2FD54C55-BFF9-43DC-9BF5-C7E82395A180

Q33903527-36AC7BBB-4E6D-4A22-BE57-5E454C6BD84C

Q33903527-3CF91A98-DF01-462B-8B3B-0E0805ACD3DB

Q33903527-3D0CA572-7A00-468C-B60F-F5D587DA5E52

Q33903527-3F31734F-EC56-42C1-A482-89A502990683

Q33903527-5DE055BD-0FE6-424B-85A8-489F1D90D701

Q33903527-777ABEF4-DD3C-4604-A78F-6735D8CDBF33

Q33903527-846E7132-3452-4472-9989-D0B0D2BFC299

P304

Q33903527-5E047754-4DC7-4BAF-AA37-1DB067E8E4D1

P31

Q33903527-4682CA02-66C6-41EA-A212-1FEC7183454E

P356

Q33903527-A0B0AE58-BFC4-4824-80F7-99182D7C5DB7

P407

Q33903527-E1A6F1E3-77E2-4E9A-9D70-25A6D0DFD4C2

P433

Q33903527-D87FC755-7BC9-4C4E-BD6F-AD4C970D15E8

P478

Q33903527-DA914CE9-C8DA-44AC-B44C-7121DE4E4D3C

P50

Q33903527-40F7266E-8AAF-4990-8F3B-16EB0211E196

Q33903527-D023A578-EBD5-4BF3-A878-D60373485B9A

Q33903527-E682EA9D-82C6-4F2B-8AB0-55D5317E614C

P577

Q33903527-531AFD52-1F0A-4145-B1CF-51F0EA2DB578

P698

Q33903527-0C5754A5-3B71-431C-B296-6E34DF789AF4

P921

Q33903527-67862EE1-1F9D-43FE-B4CF-7F4C9CBE8B1C

P932

Q33903527-5B171A8B-840A-4FC4-B2B7-0F8F9012F754

P356

WNL.0B013E3182661EB1

P1433

P1476

Tafamidis for transthyretin fa ...... a randomized, controlled trial

@en

P2093

Amy Wilson

http://www.w3.org/2001/XMLSchema#string

Ana Martins da Silva

http://www.w3.org/2001/XMLSchema#string

Donna R Grogan

http://www.w3.org/2001/XMLSchema#string

Hartmut H-J Schmidt

http://www.w3.org/2001/XMLSchema#string

Isabel Maria Conceição

http://www.w3.org/2001/XMLSchema#string

Jason Chan

http://www.w3.org/2001/XMLSchema#string

Jeff Packman

http://www.w3.org/2001/XMLSchema#string

Josep M Campistol

http://www.w3.org/2001/XMLSchema#string

Luis F Maia

http://www.w3.org/2001/XMLSchema#string

Marcia Waddington Cruz

http://www.w3.org/2001/XMLSchema#string

P2860

Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade

Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein

Quality of life following liver transplantation: a comparative study between Familial Amyloid Neuropathy and liver disease patients.

Prevention of transthyretin amyloid disease by changing protein misfolding energetics.

Transthyretin-associated neuropathic amyloidosis. Pathogenesis and treatment.

Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity.

The hereditary amyloidoses.

The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy.

Quantitative sensation and autonomic test abnormalities in transthyretin amyloidosis polyneuropathy.

Early liver transplantation is essential for familial amyloidotic polyneuropathy patients' quality of life.

P304

785-792

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/WNL.0B013E3182661EB1

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

79

http://www.w3.org/2001/XMLSchema#string

P50

Violaine Planté-Bordeneuve

Richard Labaudinière

Jeffery W. Kelly

P577

2012-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22843282

http://www.w3.org/2001/XMLSchema#string

P921

P932

4098875

http://www.w3.org/2001/XMLSchema#string